

William C Olson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/600159/publications.pdf>

Version: 2024-02-01

11
papers

1,667
citations

933447

10
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

4433
citing authors

#	ARTICLE	IF	CITATIONS
1	Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. <i>Science</i> , 2020, 369, 1010-1014.	12.6	1,140
2	Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2018, 218, S612-S626.	4.0	146
3	Characterization of the Anti-“PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 861-870.	4.1	92
4	A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	80
5	A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	70
6	Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	49
7	The impact of different human IgG capture molecules on the kinetics analysis of antibody-antigen interaction. <i>Analytical Biochemistry</i> , 2020, 593, 113580.	2.4	22
8	Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine. <i>Science Immunology</i> , 2020, 5, .	11.9	21
9	A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models. <i>Clinical Cancer Research</i> , 2020, 26, 1408-1419.	7.0	21
10	A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1966-1976.	4.1	19
11	High affinity human Fc specific monoclonal antibodies for capture kinetic analyses of antibody-antigen interactions. <i>Analytical Biochemistry</i> , 2022, 640, 114455.	2.4	6